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A B S T R A C T
Background: Young adults with depression and evidence of inflammation may represent a high-risk group for
cardiometabolic disorders, but studies of cardiometabolic risk in this population are scarce. We aimed to ex-
amine: (1) the prevalence of low-grade inflammation in young-adults with depression; (2) cross-sectional and
longitudinal associations between cardiometabolic risk factors and depression with or without evidence of in-
flammation.
Method: The ALSPAC birth cohort participants were assessed for depression and serum high-sensitivity C-
Reactive Protein (CRP) levels at age 18, alongside cardiometabolic measures (fasting insulin, fasting plasma
glucose, low-density lipoprotein, high-density lipoprotein, triglycerides, smoking, alcohol intake) at age 18
years, and body mass index at ages 9, 13 and 18 years. Low-grade inflammation was defined as CRP>3mg/L.
Multinomial regression was used to examine associations of cardiometabolic markers with depression cases with
and without evidence of inflammation. Sensitivity analyses were conducted to examine for interactions between
depression, inflammation and cardiometabolic traits.
Results: Out of 2932 participants, 215 met ICD-10 criteria for depressive episode at age 18 years; 23 (10.7 %)
had CRP>3mg/L and 57 (26.5 %) had CRP 1−3mg/L. Depressive episode with raised CRP (> 3mg/L) was
associated with higher triglycerides (adjusted OR=2.09; 95 % C.I., 1.35−3.24), higher BMI (adjusted
OR=1.13; 95 % C.I., 1.05−1.22) and insulin insensitivity (adjusted OR=1.12; 95 % C.I., 1.01−1.26), and
longitudinally with higher BMI at ages 9 (adjusted OR=1.27; 95 % C.I., 1.10−1.48) and 13 (adjusted
OR=1.23; 95 % C.I., 1.09−1.38). There was evidence for interaction between BMI and CRP for the risk of
depression at age 18 (adjusted OR for the interaction term=1.56; 95 % C.I. 0.98–2.02) and between CRP and
depressive symptoms for the risk of increased BMI at age 18 (adjusted β for the interaction term=0.05; 95 %
C.I. 0.00−0.12).
Conclusions: A notable proportion of young adults with depression have evidence of inflammation. These in-
dividuals are at increased risk of cardiometabolic disorders. Management of cardiometabolic risk in depressed
individuals with evidence of inflammation should form part of routine clinical practice.
1. Introduction
Low-grade inflammation is implicated in pathogenesis of depression
(Lee and Giuliani, 2019; Miller et al., 2009; Miller and Raison, 2016)
and is associated with increased cardiovascular and all-cause mortality
(Proctor et al., 2015). Meta-analyses of cross-sectional studies have
reported that depressed patients have higher mean concentrations of
inflammatory markers such as C-reactive protein (CRP) and interleukin
6 (IL-6) in peripheral blood compared with controls (Haapakoski et al.,
2015; Howren et al., 2009; Leighton et al., 2018). Longitudinally,
higher levels of inflammatory markers in childhood are associated with
risks of depression and persistent depressive symptoms subsequently in
early-adulthood (Khandaker et al., 2014, 2018). A recent systematic
review and meta-analysis reported that about a quarter of depressed
patients have evidence of low-grade inflammation, defined as circu-
lating CRP levels> 3mg/L (Osimo et al., 2018). However, the majority
of included studies were case-control by design, and based on hospital-
treated or treatment-resistant working-age adults (Raison et al., 2013;
Uher et al., 2014; Wium-Andersen et al., 2013; Wysokinski et al., 2015),
which increases the possibility of selection bias and confounding by
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comorbid inflammatory physical illness or lifestyle factors. General
population-based studies examining the prevalence of low-grade in-
flammation in depression are scarce, and to our knowledge, no popu-
lation-based study has examined the prevalence of inflammation in
depression in young adults. Studies conducted on younger populations
may be beneficial as participants may be less affected by chronic phy-
sical illness or lifestyle factors.
People with depression who have evidence of inflammation may
represent a high-risk group for cardiometabolic disorders. Co-morbidity
of depression with cardiovascular diseases (CVD) (Anda et al., 1993),
type 2 diabetes mellitus (T2DM) (Roy and Lloyd, 2012) and obesity
(Luppino et al., 2010) is well established, and there is evidence for
genetic overlaps between depression, inflammation and obesity
(Milaneschi et al., 2017). Inflammation is associated with insulin re-
sistance (IR) (Belgardt et al., 2010), CVD (Danesh et al., 2008) and
T2DM (Rader, 2007). We recently reported that inflammation could be
a shared mechanism for CVD and depression using MR analysis of UK
Biobank data (Khandaker et al., 2019a, 2019b). Depression is asso-
ciated with cardiometabolic risk factors, such as obesity, altered lipid
profile and IR in working age adults (Martin et al., 2016; Timonen et al.,
2006). There is also some evidence for these associations in younger
adults, though they may be explained by sociodemographic and life-
style factors (Perry et al., 2020). It has been proposed that “immuno-
metabolic depression” may represent a particular ‘sub-type’ of depres-
sion characterised by distinct symptom profile (e.g., increased appetite
and weight gain) and increased inflammatory and cardiometabolic
markers (Lamers et al., 2018; Penninx et al., 2013; Simmons et al.,
2018). However, it remains unclear how far back in the life-course an
altered immuno-metabolic signature may be detectable.
Based on data from the Avon Longitudinal Study of Parents and
Children (ALSPAC), a general population-representative prospective
birth cohort from the UK, we have examined the prevalence of low-
grade inflammation (serum hsCRP levels> 3mg/L) in participants
meeting the ICD-10 criteria for current depressive episode at age 18
years. We have compared cardiometabolic risk between depression
with and without evidence of inflammation using a range of established
cardiometabolic risk factors at age 18 years and body mass index (BMI)
in childhood at ages 9 and 13 years. We hypothesized that depression
with evidence of inflammation would be associated with greater car-
diometabolic risk both cross-sectionally and longitudinally.
2. Methods
2.1. Description of cohort and sample
The Avon Longitudinal Study of Parents And Children (ALSPAC)
birth cohort initially recruited 14,541 pregnant women resident in
county Avon, a geographically defined region in southwest of England,
with expected dates of delivery 1 st April 1991 to 31 st December 1992,
resulting in 14,062 live births (Boyd et al., 2013; Fraser et al., 2013).
Detailed information about the ALSPAC cohort can be found on the
study website (http://www.bristol.ac.uk/alspac). The study website
contains details of all available data through a fully searchable “data
dictionary” (http://www.bris.ac.uk/alspac/researchers/data-access/
data-dictionary/). Parents completed regular postal questionnaires
about all aspects of their child’s health and development from birth.
Since age 7, the children attended an annual assessment clinic during
which they participated in various face-to-face interviews and physical
tests.
The current study is based on all participants with a measure of the
outcome and exposures, after removing participants with CRP > 10
(Khandaker et al., 2014), to minimize the potential confounding effect
of ongoing or recent inflammatory disease/infection, or treatment for
such conditions. The total sample included 2918 complete cases at age
18 years (mean age= 17.8; SD=0.38). See Supplementary Fig. 1 for a
flow-chart of participants in the study. The authors assert that all
procedures contributing to this work follow the ethical standards of the
relevant national and institutional committees on human experi-
mentation and with the Helsinki Declaration of 1975, as revised in
2008. All procedures involving human subjects/patients were approved
by
the ALSPAC Law and Ethics Committee, and Local Research Ethics
Committees. All participants provided informed consent.
2.2. Outcome
2.2.1. Measurement of high sensitivity CRP at age 18 years
In total, 3287 participants provided a blood sample. Samples were
frozen at −80 °C. The measurements were assayed in 2008 after a
median of 7.5 years in storage. There was no evidence of freeze-thaw
cycles during storage period. CRP was measured by automated particle-
enhanced immunoturbidimetric assay (Roche UK, Welwyn Garden City,
UK). All assay coefficients of variation were< 5%. The minimum de-
tection limit for CRP was 0.03mg/L. Twenty-nine participants (0.6 % of
the sample) were below this limit and were assigned values of 0.01
(n= 16) and 0.02 (n=13); they were also included in the analysis. In
the total sample, CRP values ranged from 0.01–176.10mg/L (32 sub-
jects had CRP levels> 10mg/L). Participants with CRP > 10mg/L
(n= 32) were excluded due to the risk of confounding by acute in-
flammatory state (e.g. infection). We defined evidence of low-grade
inflammation as serum CRP>3mg/L, and no inflammation as
CRP<3mg/L, as is most commonly used in the literature to define
low-grade inflammation (Osimo et al., 2018). In addition, we treated
CRP as a categorical variable. We created three groups based on CRP
levels (< 1mg/L; 1–3mg/L;> 3mg/L) according to the American
Heart Association (AHA) and Centers for Disease Control and Preven-
tion (CDC), USA, guidelines on categorising high-sensitivity CRP levels
for cardiovascular studies (Pearson et al., 2003). See Supplementary
Methods for further information on measurement of CRP.
2.2.2. Assessment of depression at age 18 years
The computerised version of the Clinical Interview Schedule
Revised (CIS-R) was self-administered by cohort participants in as-
sessment clinics at mean age 17.8 years (SD=0.38). The CIS-R is a
widely used, standardized tool for measuring common mental disorders
in large community samples (Lewis et al., 1992). The CIS-R is a fully
structured assessment, suitable for trained social survey interviewers
and does not require any expert knowledge on the part of the inter-
viewers. As such, it can also be administered using personal computers
in which the subjects self-complete the questionnaire (Lewis, 1994).
The CIS-R elicits responses to depressive symptoms experienced in the
preceding week, and provides a diagnosis of current depressive episode
according to ICD-10 criteria (WHO, 1992). ICD-10 current depressive
episode was used as the main binary outcome measure. In sensitivity
analysis, we also used a continuous measure of depressive symptoms
score as secondary outcome measure (score range 0–21). This score was
created by summing symptom scores for depression, depressive
thoughts, fatigue, concentration, and sleep problems also assessed using
CIS-R.
2.3. Exposures
2.3.1. Cardiometabolic risk factors at age 18 years
2.3.1.1. Glucose-insulin homeostasis. We used the biochemical
measurements of fasting plasma glucose (FPG) and fasting insulin
(FI). Fasting samples were taken at 0900 after a 10 -h fast (water
only). Blood samples were immediately spun, frozen and stored at
−80 °C and measurements were assayed within 3–9 months of the
samples being taken with no previous freeze-thaw cycles. FPG and FI
were measured by an ultrasensitive ELISA (Mercodia, Uppsala, Sweden)
automated microparticle enzyme immunoassay. Its sensitivity was 0.07
mU/L, and inter- and intra-assay coefficients of variation were<6%.
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Insulin resistance was calculated as a continuous measure from FPG and
FI by using the computerized, updated version of the Homeostatic
Model Assessment (HOMA2) for Insulin Resistance (Levy et al., 1998).
The algorithm generates a relatively precise measurement of IR taking
into account variations in hepatic and peripheral glucose resistance,
increases in the insulin secretion curve for plasma glucose
concentrations above 10mmol/L (180mg/dL) and the contribution of
circulating proinsulin (Levy et al., 1998).
2.3.1.2. Lipid Metabolism. We used biochemical measurements of high-
density lipoprotein (HDL), low-density lipoprotein (LDL) and
triglycerides (TG). Fasting samples were taken at 0900 after a 10 -h
fast (water only). Plasma lipid concentrations were measured by
modification of the standard Lipid Research Clinics Protocol by using
enzymatic reagents for lipid determination. LDL concentration was
determined via the Friedwald equation (LDL= total cholesterol –
(HDL+TG*0.45)).
2.3.1.3. Smoking and alcohol use. Self-reported data on smoking,
alcohol and drug use were collected using a questionnaire. The
number of cigarettes/roll ups smoked per day was coded as a binary
variable if participant reported smoking ≥1 cigarette per day. Alcohol
use was coded as a binary variable if participants reported consuming
drinks containing alcohol twice a week or more frequently.
2.3.2. Assessment of BMI at Ages 9, 13 and 18 Years
BMI was calculated as weight (kilograms) divided by height (metre
squared) and was measured at various timepoints in a relatively large
sample during childhood.
2.4. Assessment of potential confounders
We adjusted cross-sectional analyses for sex, ethnicity, paternal
social class, physical activity (questionnaire data, binary based on
participating in physical exercise e.g. gym attendance, brisk walking or
any sports activity at least once per week over the preceding year),
smoking (age 18 questionnaire data, binary based upon reporting
smoking at least one cigarette per day on average over the preceding
year), alcohol use (age 18 questionnaire data, binary, based upon
consuming drinks containing alcohol at least twice per week on average
over the preceding year), and BMI (age 18 clinic data, continuous). For
our longitudinal analysis, we adjusted for sex, ethnicity and paternal
social class. We excluded adjustment variables where they were the
exposure of interest, since they were already apparent in the statistical
model. See Supplementary Data for further information.
2.5. Statistical analysis
Exposures that were non-normally distributed were natural log-
transformed (all variables except FPG). Resultant variables were stan-
dardized (Z-transformed), so the statistical estimations represent the
increase in risk of depression (with or without raised CRP) per SD in-
crease in exposure. We completed tests for multi-collinearity of ex-
posures/confounders in a linear regression model. The variance infla-
tion factor for all covariates was between 1.01–1.11, suggesting
minimal multi-collinearity. Adjustments were added using the enter
method of multiple regression. All statistical analysis was done using
IBM SPSS 24.0.
2.5.1. Prevalence of depression with evidence of inflammation
We calculated the proportion of currently depressed participants
with “low”, “medium” and “high” inflammation at age 18 years, com-
pared with non-depressed participants. Chi-square tests were used to
examine for differences between currently depressed and non-de-
pressed participants in CRP levels, and for associations between se-
verity of depression and CRP levels.
2.5.2. Associations between cardiometabolic risk factors and depression
with evidence of inflammation
We used multinomial regression to calculate odds ratios (ORs) and
95 % confidence intervals (C.I.) for the cross-sectional and longitudinal
associations between cardiometabolic risk factors and depression with
or without evidence of raised CRP. ‘No depression’ was the reference
category. We performed likelihood ratio tests to examine whether the
estimates for groups were significantly different from each other.
Multinomial regression models were adjusted for potential confounders
as described above. ORs represent the increase in risk of depression
with/without evidence of raised CRP per standard deviation (SD) in-
crease in exposure variable, compared to participants with no depres-
sive episode.
2.5.3. Interactions between CRP and cardiometabolic factors on risk of
depression
We performed a sensitivity analysis to examine for any cross-sec-
tional association or interaction between CRP (continuous data) and the
cardiometabolic factors described above, on risk of current depression
at age 18 years. We performed adjustments as described above. For
each cardiometabolic risk factor, we included CRP in the logistic
Fig. 1. Cases of Mild, Moderate and Severe Depression at Age 18 years Grouped by Serum CRP Level.
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regression model alongside an interaction term (CRP*cardiometabolic
risk factor). ORs represent the increase in risk of depression per stan-
dard deviation (SD) increase in exposure or interaction variable, com-
pared to participants with no depressive episode.
2.5.4. Interactions between CRP and depression on cardiometabolic risk
We performed a sensitivity analysis to examine for any cross-sec-
tional association of CRP (continuous data) and interaction between
CRP and depressive symptom score (continuous data), for the outcomes
of cardiometabolic traits (continuous data). Regression models were
adjusted as described above. For each continuous cardiometabolic
outcome, we included CRP and depressive symptom score in a linear
regression model alongside an interaction term (CRP*depressive
symptom score). Beta coefficients and 95 % C.I’s represent estimates for
the SD increase in continuous cardiometabolic trait per SD increase in
exposure or interaction variable.
2.5.5. Multiple testing correction
p-values for adjusted regression models for cross-sectional analyses
were corrected for multiple testing using the Holm-Bonferroni method
(Holm, 1979).
3. Results
3.1. Sample characteristics and prevalence of depression with evidence of
inflammation at age 18 years
Table 1 presents the baseline characteristics of the sample. Out of
2932 participants with data on CRP and depression at age 18 years, 215
met ICD-10 criteria for current depressive episode (7.3 %). The number
of participants with mild, moderate, and severe depressive episode was
92 (42 %), 95 (44 %) and 28 (14 %) respectively. Out of 215 cases of
current depression, 135 (62.7 %) had CRP<1mg/L, 57 (26.5 %) had
CRP 1−3mg/L, and 23 (10.7 %) had CRP>3mg/L (see Table 2;
Supplementary Figure 2). There was trend level evidence for differences
between depressed and non-depressed participants’ CRP levels
(χ2= 5.56; p=0.062), and increased levels of CRP with increasing
severity of depression (χ2=4.84; p=0.089) (Fig. 1).
3.2. Cross-sectional associations between cardiometabolic risk factors and
depression with and without evidence of inflammation at age 18 years
Female sex was associated with current depression, both in groups
with raised CRP (OR=7.83; 95 % C.I., 1.78−34.40) and without
(OR=2.35; 95 % C.I., 1.64−3.35), but the association was stronger for
cases with raised CRP (Holm-corrected p-value for likelihood ratio
test< 0.001) (Table 3). BMI (OR=1.13; 95 % C.I., 1.05−1.22),
HOMA2 (OR=1.12; 95 % C.I., 1.01−1.26), triglycerides (OR=2.09;
95 % C.I., 1.35−3.24) and fasting insulin (OR=1.42; 95 % C.I., 1.01-
2.12) were associated with current depression with raised CRP, after
adjusting for potential confounders. The likelihood ratio test showed
that these effect estimates were significantly different between the two
depressed groups (Table 4), though only the p-value for the likelihood
ratio test for triglycerides survived multiple testing correction.
3.3. Longitudinal associations between childhood BMI and depression with
and without evidence of inflammation at age 18 years
Higher BMI at both ages 9 (OR=1.27; 95 % C.I. 1.10−1.48) and
13 (OR=1.23; 95 % C.I. 1.09−1.38) years was associated with de-
pression with raised CRP at age 18 years (See Table 5).
3.4. Interactions between CRP and cardiometabolic factors on risk of
depression
We found trend evidence for an interaction between CRP and BMI
(adjusted OR for the interaction term=1.56; 95 % C.I. 0.98–2.02) and
between CRP and triglycerides (adjusted OR for the interaction
term=1.17; 95 % C.I. 0.99–1.38) on risk of current depression. See
Supplementary Table 1.
3.5. Interactions between CRP and depressive symptom score on
cardiometabolic risk
We found trend level evidence for an interaction between CRP and
depressive symptom score for the outcome of BMI (adjusted β for the
Table 1
Characteristics of Sample with Data on Depression and CRP at Age 18 Years in the ALSPAC Birth Cohort.
Characteristic Total Sample No depression Depression with Inflammation (CRP >3mg/L) Depression without Inflammation (CRP <3mg/L)
Participants, n (% total) 2932 (100) 2717 (93) 23 (1) 192 (6)
Male Sex, n (%) 1426 (48) 1368 (50) 3 (13) 55 (29)
Paternal Social Class, n (%)
I & II 1165 (39) 1091 (36) 6 (26) 68 (35)
III – non-manual & manual 1169 (39) 1082 (37) 12 (52) 76 (39)
IV & V 598 (20) 544 (18) 5 (22) 49 (13)
White British Ethnicity, n (%) 2873 (98) 2663 (98) 22 (95) 188 (98)
BMI at 18y, mean (SD) 22.66 (3.80) 22.64 (3.76) 25.90 (5.81) 22.69 (4.05)
BMI at 13y, mean (SD) 20.17 (3.16) 20.12 (3.13) 23.08 (3.30) 20.38 (3.18)
BMI at 9y, mean (SD) 17.51 (2.59) 17.48 (2.59) 20.20 (2.26) 17.59 (2.41)
FPG at 18, mean (SD), mmol/L 5.03 (0.47) 5.03 (0.44) 4.95 (0.75) 5.02 (0.83)
HOMA2 at 18y, mean (SD) 0.92 (0.73) 0.92 (0.74) 0.93 (0.44) 0.98 (0.72)
CRP at 18y, mean (SD), mg/L 1.09 (1.43) 1.09 (1.43) 4.53 (1.48) 0.82 (0.72)
Smoking at age 18, n (%) 211 (7) 185 (7) 2 (9) 24 (13)
Depression score at age 18, mean (SD) 3.09 2.39 (2.91) 12.57 (3.63) 11.98 (3.56)
Physical Activitya at 18y, n (%) 1964 (67) 1901 (70) 7 (30) 57 (29)
Alcohol Useb at 18y, n (%) 1172 (40) 1059 (39) 11 (48) 102 (53)
aPhysical activity measured as a binary variable based upon average weekly frequency of at least once per week of going to gym, brisk walking, or any sports activity
during the past year.
bAlcohol use measured as a binary variable based upon average weekly frequency of at least 2 times per week participant has consumed drinks containing alcohol.
Table 2
Prevalence of low, medium and high CRP levels in Participants with and
without ICD-10 Current Depressive Episode at age 18 years.
CRP Level (age 18) No Depressive episode
at 18y, n (%)
Depressive Episode
at 18y, n (%)
χ2 (df), p-
value
< 1mg/L 1896 (68.2) 135 (62.7) 5.56 (2),
0.0621−3mg/L 728 (26.1) 57 (26.5)
> 3mg/L 157 (5.6) 23 (10.7)
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interaction term=0.05; 95 % C.I. 0.00−0.12). CRP was associated
with other cardiometabolic outcomes after controlling for potential
confounders: HOMA2 (adjusted β=0.11; 95 % C.I., 0.03−0.19),
fasting insulin (adjusted β=0.10; 95 % C.I., 0.02−0.18), HDL (ad-
justed β=-0.23; 95 % C.I.,−0.31 to−0.15) and triglycerides (adjusted
β=0.22; 95 % C.I., 0.14−0.30). However, there was no evidence for
interaction between CRP and depressive symptoms scores in relation to
these outcomes.
4. Discussion
Using a general population-based birth cohort study, we report that
a notable proportion of young adults with current depression have
evidence of raised CRP. In our sample, approximately one in ten people
meeting ICD-10 criteria for current depressive episode at age 18 had
CRP>3mg/L, while about a quarter had CRP 1−3mg/L. To our
knowledge, this is one of the first studies of the prevalence of low-grade
inflammation in young adults enrolled in a population-representative
birth cohort. The meta-analytic prevalence of inflammation defined as
CRP>3mg/L is about 27 % (Osimo et al., 2018), and in individual
Table 3
Sociodemographic Factors Associated with Depression With and Without Evidence of Inflammation at Age 18 years.














OR (95 % CI) OR (95 % CI) X2 p-value Corrected p-
valued
OR (95 % CI) OR (95 % CI) X2 p-value Corrected p-
valued
Female Sex 6.77 (2.01−22.82) 2.53 (1.83−3.49) 48.26 <0.001 <0.001 7.83 (1.78−34.40) 2.35 (1.64−3.35) 34.56 < 0.001 <0.001
Non-White
Ethnicityb
2.81 (0.37−21.49) 0.56 (0.14−2.31) 1.52 0.468 0.468 4.44 (0.56−35.25) 0.86 (0.20−3.62) 1.43 0.490 0.490
Paternal Social
Classc
1.08 (0.88−1.33) 1.07 (0.99−1.15) 3.27 0.195 0.390 1.09 (0.89−1.35) 1.06 (0.99−1.15) 3.31 0.191 0.382
a Regression models were adjusted for sex, ethnicity, paternal social class, smoking, alcohol use, physical activity, BMI (age 18 years).
b The group with British White ethnicity was used as reference; non-white ethnic groups included Bangladeshi, Indian, Pakistani, Chinese, Black Caribbean, Black
African, and Other.
c Paternal social class defined as the social class of the father at birth. Class I (professional) was used as reference.
dp-values corrected for multiple testing using the Holm-Bonferroni method.
Table 4
Cross-sectional Associations of Cardiometabolic Risk Factors with Depression With and Without Evidence of Inflammation at Age 18 Years.














OR (95 % CI) OR (95 % CI) X2 p-value Corrected p-
valueb
OR (95 % CI) OR (95 % CI) X2 p-value Corrected p-
valueb
BMI 1.14 (1.06−1.21) 1.00 (0.96−1.04) 10.71 0.005 0.040 1.13 (1.05−1.22) 1.00 (0.96−1.04) 8.94 0.011 0.088
HOMA2 1.17 (1.01−1.36) 1.12 (0.96−1.29) 6.44 0.039 0.234 1.12 (1.01−1.26) 1.01 (0.91−1.18) 5.99 0.046 0.230
FPG 0.76 (0.49−1.18) 0.92 (0.78−1.18) 2.38 0.304 1.000 0.92 (0.52−1.66) 1.07 (0.90−1.28) 0.68 0.712 1.000
FI 1.46 (1.02−2.10) 1.13 (0.96−1.31) 6.25 0.044 0.234 1.42 (1.01−2.12) 1.15 (0.94−1.33) 2.39 0.030 0.180
HDL 0.82 (0.56−1.19) 1.08 (0.93−1.25) 2.12 0.347 1.000 0.75 (0.53−1.08) 0.95 (0.80−1.12) 2.23 0.329 1.000
LDL 1.35 (0.87−2.08) 0.99 (0.86−1.14) 1.90 0.387 1.000 1.28 (0.76−2.11) 0.95 (0.80−1.12) 1.38 0.501 1.000
TG 1.92 (1.33−2.76) 1.02 (0.88−1.18) 11.47 0.003 0.027 2.09 (1.35−3.24) 0.93 (0.79−1.10) 11.33 0.003 0.027
Smoking 1.30 (0.30−5.60) 1.96 (1.24−3.07) 7.43 0.024 0.168 0.84 (0.11−6.55) 2.26 (1.37−3.74) 8.99 0.011 0.088
Alcohol 0.86 (0.55−1.21) 1.09 (0.77−1.45) 2.03 0.299 1.000 0.80 (0.50−1.18) 1.08 (0.79−1.43) 2.01 0.301 1.000
BMI=Body Mass Index; HOMA2=Homeostatic Model Assessment; FPG=Fasting Plasma Glucose; FI= Fasting Insulin; HDL=High-Density Lipoprotein;
LDL=Low-Density Lipoprotein; TG=Triglycerides; PE=’Definite’ Psychotic Experiences. BMI, HOMA2, FPG, FI, HDL, LDL, TG coded as continuous variables.
Smoking, Drug Use and Alcohol coded as categorical variables.
aRegression models were adjusted for sex, ethnicity, paternal social class, physical activity, smoking, alcohol use and BMI (age 18 years) bp-values corrected for
multiple testing using the Holm-Bonferroni method.
Table 5
Longitudinal associations between Childhood BMI and Depression With and Without Evidence of Inflammation at Age 18 Years.


















Variable n OR (95 % C.I.) OR (95 % C.I.) χ² p-value OR (95 % C.I.) OR (95 % C.I.) χ²
BMI (age 9) 2571 1.31 (1.15−1.49) 1.02 (0.96−1.08) 14.14 0.001 1.27 (1.10−1.48) 1.02 (0.96−1.09) 8.63 0.013
BMI (age 13) 2462 1.23 (1.11−1.37) 1.03 (0.98−1.08) 13.76 0.001 1.23 (1.09−1.38) 1.02 (0.96−1.08) 9.85 0.007
aRegression models were adjusted for sex, ethnicity, paternal social class. BMI=Body Mass Index.
B.I. Perry, et al. Psychoneuroendocrinology 116 (2020) 104682
5
studies this prevalence ranges from 19 to 47% (Uher et al., 2014; Wium-
Andersen et al., 2013; Wysokinski et al., 2015). The relatively lower
prevalence in our sample could be due to participant age and recruit-
ment method. The majority of previous studies included older partici-
pants, increasing the likelihood of comorbid inflammatory physical
illness or inflammatory-related lifestyle factors such as smoking (Lee
et al., 2012), and many of these studies recruited participants from
hospital inpatient or outpatient department, possibly missing milder
cases of depression.
We report that participants with a current depressive episode and
raised CRP were more likely to be female and have increased cardio-
metabolic risk factors at age 18 years, and increased BMI in childhood
assessed at ages 9 and 13. Our findings may indicate that depression
with evidence of inflammation may be more common in females.
However, in our sample there were only three male participants who
had depression and evidence of inflammation. Therefore, the possibility
of type I error due to low statistical power because of small sample size
cannot be ruled out. In future, studies with larger samples of depressed
cases are required.
Cardiometabolic risk factors were associated with cases of current
depression with, but not without, evidence of inflammation. These
findings are consistent with the idea that inflammation could be a
common mechanism for comorbid depression and cardiometabolic
disorders. Comorbidity between depression and cardiometabolic dis-
orders is well known (Vancampfort et al., 2016), and is present even in
young people (Lin et al., 2014). We found the evidence for an asso-
ciation of current depression with raised CRP and raised triglycerides,
which is consistent with our recent MR study reporting that triglycer-
ides, as well as IL-6 and CRP, could be causally linked to depression
(Khandaker et al., 2019a, 2019b). In future, studies should examine
mechanisms through which alterations in triglycerides contribute to
depression risk to elucidate potential therapeutic targets.
Previous research which considered depression as a single entity,
including our own work from the ALSPAC cohort, reported that asso-
ciations between current depression and cardiometabolic risk factors
could be explained by sociodemographic and lifestyle factors including
sex, ethnicity, social class and physical activity (Perry et al., 2020). In
the current study, we report that evidence for association between a
current depressive episode with evidence of inflammation and cardio-
metabolic risk factors remains after adjustments for potential con-
founders, which aligns with other research (Rethorst et al., 2014). We
also found an interaction between CRP and both BMI and triglycerides
on risk of depression, suggesting that inflammation and cardiometa-
bolic factors work together to increase the risk of depression. In addi-
tion, we also found some evidence for an interaction between CRP and
depressive symptom score for the outcome to BMI, suggesting that in-
flammation and depressive symptoms may work together to increase
BMI. These results are consistent with the concept of a distinct phe-
notype of ‘immuno-metabolic depression’ (Penninx et al., 2013). Im-
muno-metabolic depression has previously been linked with distinct
depressive symptomatology such as increased appetite disturbance,
weight gain (Lamers et al., 2018), and depressed patients with these
symptoms have been found to have higher BMI and CRP levels (Lamers
et al., 2013) alongside other cardiometabolic alterations such as insulin
resistance (Simmons et al., 2018).
Cardiometabolic traits are known to be associated with inflamma-
tion (Bulló et al., 2003; Calabro and Yeh, 2008; Jung and Choi, 2014).
Our sensitivity analyses showed that CRP was associated with several
cardiometabolic factors (HOMA2, fasting insulin, triglycerides, and
HDL) after adjustments for potential confounders including depressive
symptoms. HOMA2 is a reliable measure of insulin resistance (Geloneze
et al., 2009) and the triad of raised fasting insulin, triglycerides and low
HDL can reflect an insulin resistant state (Glueck et al., 2009). Insulin
resistance is known to be closely related to inflammatory processes
(Chen et al., 2015). Our results suggest that BMI may be mechan-
istically associated with depression plus evidence of inflammation,
while glycaemic traits may arise secondary to the inflammation or by
other mechanisms.
Our longitudinal analyses revealed that raised BMI measured in
childhood was associated with current depression with raised CRP
subsequently at age 18. This finding indicates that underlying biolo-
gical processes predisposing to cardiometabolic alterations and de-
pression may begin early in the life-course. A growing body of research
is beginning to implicate that the cardiometabolic comorbidity asso-
ciated with depression may originate, in part, from pathogenic pro-
cesses initiated in fetal development (Goldstein et al., 2019). For ex-
ample, maternal prenatal glucocorticoid excess and immune pathway
abnormalities are associated with sex-dependent impacts on offspring
brain circuitry, resulting in depression alongside dysregulation of im-
mune responses and an increased risk of cardiometabolic disorders in
adulthood (Domes et al., 2010; Monroe and Harkness, 2005; Pacak
et al., 1995).
Strengths of the work include use of data from a prospective general
population-representative birth cohort, inclusion of a range of cardio-
metabolic markers, and longitudinal design. The participants in our
study were relatively young, thus reducing the chance of confounding
by chronic physical comorbidity or the effects of long-term poor diet,
limited exercise, smoking, alcohol use and psychological stress. We
were able to adjust for several potential confounders including age, sex,
ethnicity, social class, physical activity, alcohol and substance use and
BMI.
Limitations of this work include, as with all observational research,
residual confounding. We were unable to adjust for psychotropic
medication since this data were not available. However, whilst certain
antidepressants may predispose to cardiometabolic dysfunction, this is
unlikely to affect our longitudinal analysis, since psychotropic medi-
cation prescription in childhood is relatively rare. Other immuno-
modulatory medications or inflammatory physical illness may also have
influenced the CRP data we used in the study. We attempted to address
the impact of this potential limitation by excluding participants with
CRP>10mg/L as an indicator of possible acute inflammatory process.
Future work may seek to make attempts to more accurately account for
the risk of confounding by medication. Whilst we were able to measure
a definition of depression meeting ICD-10 criteria, the CIS-R elicits
symptoms of depression suffered in the previous week. Therefore, our
findings are reflective of a depressed state and it is unclear how our
results may be extrapolated to trait depression. Future research may
seek to replicate our work with cases of persistent or recurrent de-
pression and evidence of inflammation. Another issue is attrition. Only
a subset of the cohort undertook assessment for depression at age 18,
and not all those participants had data for the exposures and covariates.
Selective attrition of depressed individuals could introduce a bias to-
wards the null, thus our analysis might underestimate the true asso-
ciation between depression and cardiometabolic risk factors. Whilst we
included a relatively large overall sample, the numbers of participants
with evidence of raised CRP and depression was relatively small. Future
research conducted on larger samples of people with depression may be
warranted to confirm our findings. Finally, whilst we considered CRP as
an indicator of inflammation, because it is the most commonly mea-
sured inflammatory biomarker in hospital laboratories, future research
may seek to examine a greater range of inflammatory biomarkers.
5. Conclusions
In summary, our findings suggest that depression with evidence of
inflammation represents a high-risk state for cardiometabolic disorders.
Therefore, clinicians should need to proactively assess and manage
cardiovascular risk in people presenting with depression who show
evidence of inflammation to improve long-term health outcomes.
Evidence for the longitudinal association with childhood BMI indicates
that cardiometabolic alterations in young adults presenting with de-
pression are unlikely to be fully explained by reverse causality or by
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confounding from lifestyle factors. The findings are consistent with the
idea that inflammation could be a shared mechanism for depression and
cardiovascular disease.
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